Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 932-942

  Gabrielsson, Linda ^a   Mattsson, Sofia ^a   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

adverse drug reactions; clinical trials; inflammation; pain; Palmitoylethanolamide; pharmacokinetics

Indexed keywords

PALMIDROL;

ANALGESIC ACTIVITY; CLINICAL TRIAL (TOPIC); CONSTIPATION; CREAM; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; PAIN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; VOMITING;

EID: 84986296799     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13020     Document Type: Review

References (67)

1. Coburn A, Graham C, Haninger J. The effect of egg yolk in diets on anaphylactic arthritis (passive arthus phenomenon) in the guinea pig. J Exp Med 1954; 100: 425–35.
2. Kuehl F, Jacob T, Ganley O, Ormond R, Meisinger M. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc 1957; 79: 5577–8.
3. Hansen HS. Effect of diet on tissue levels of palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12: 17–25.
4. Kahlich R, Klíma J, Cihla F, Franková V, Masek K, Rosicky M, et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 1979; 23: 11–24.
5. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993; 39: C145–7.
6. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996; 300: 227–36.
7. Jaggar S, Sellaturay S, Rice A. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder. Neurosci Letts 1998; 253: 123–6.
8. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277–81.
9. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 2001; 419: 191–8.
10. Capasso R, Izzo A, Fezza F, Pinto A, Capasso F, Mascolo N, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 2001; 134: 945–50.
11. Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol 2001; 12: 29–39.
12. Farquhar-Smith W, Jaggar S, Rice A. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1and CB2-like receptors. Pain 2002; 97: 11–21.
13. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15–9.
14. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain 2008; 139: 541–50.
15. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009; 613: 54–9.
16. De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011; 7: 3.
17. Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E, et al. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 2012; 26: 1310–21.
18. Romero TRL, Duarte IDG. N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation. J Pharmacol Sci 2012; 118: 156–60.
19. Di Paola R, Impellizzeri D, Mondello P, Velardi E, Aloisi C, Cappellani A, et al. Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice. Shock 2012; 38: 356–66.
20. Keppel Hesselink JM. New targets in pain, non-neuronal cells, and the role of palmitoylethanolamide. Open Pain J 2012; 5: 12–23.
21. Paladini A, Fusco M, Cenacci T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician 2016; 19: 11–24.
22. Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today 2014; 19: 1632–9.
23. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol Res 2014; 86: 32–41.
24. Lowin T, Apitz M, Anders S, Straub RH. Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther 2015; 17: 321.
25. Overton H, Babbs A, Doel S, Fyfe M, Gardner L, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3: 167–75.
26. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009; 201: 219–30.
27. Dalle Carbonare M, Del Giudice E, Stecca A, Colavito D, Fabris M, D'Arrigo A, et al. A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story. J Neuroendocrinol 2008; 20 (Suppl 1): 26–34.
28. Vacondio F, Bassi M, Silva C, Castelli R, Carmi C, Scalvini L, et al. Amino acid derivatives as palmitoylethanolamide prodrugs: synthesis, in vitro metabolism and in vivo plasma profile in rats. PLoS One 2015; 10: e0128699.
29. Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol 2016; 173: 1154–62.
30. Grillo SL, Keereetaweep J, Grillo MA, Chapman KD, Koulen P. N-Palmitoylethanolamine depot injection increased its tissue levels and those of other acylethanolamide lipids. Drug Des Devel Ther 2013; 7: 747–52.
31. Artamonov M, Zhukov O, Shuba I, Storozhuk L, Khmel T, Klimashevsky V, et al. Incorporation of labelled N-acylethanolamine (NAE) into rat brain regions in vivo and adaptive properties of saturated NAE under x-ray irradiation. Ukr Biokhim Zh 2005; 77: 51–62.
32. Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004; 123: 131–45.
33. Stevens SS. On the theory of scales of measurement. Science 1946; 2684: 677–80.
34. Joyce CR, Zutshi DW, Hrubes V, Mason RM. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol 1975; 6: 415–20.
35. Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. J Low Genit Tract Dis 2013; 17: 111–6.
36. Song F, Hooper L, Loke YK. Publication bias: what is it? How do we measure it? How do we avoid it? Open Access J Clin Trials 2013; 5: 71–81.
37. Bacci C, Cassetta G, Emanuele B, Berengo M. Randomized split-mouth study on postoperative effects of palmitoylethanolamide for impacted lower third molar surgery. ISRN Surg 2011; 2011: 917350.
38. Wen W, Sitar S, Lynch SY, He E, Ripa SR. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Expert Opin Pharmacother 2015; 16: 1593–606.
39. Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93–4.
40. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686–95.
41. Guida G, De Martino M, De Fabiani A, Cantieri LA, Alexandre A, Vassallo GM, et al. La palmitoilethanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolor 2010; 25: 35–42.
42. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain 2012; 26: 99–104.
43. Canteri L, Petrosino S, Guida G. Riducción del consumo di antiinfiammatorios y analgésicos en el tratamiento del dolor neuropático crónico en pacientes afectados por lombosciatalgia de tipo compresivo y en tratamiento con Normast®300 mg. Dolor 2010; 25: 227–34.
44. Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 2011; 158: 82–6.
45. Kriek R. Marketing messages in pharmacological papers and scientific chapters: The case of palmitoylethanolamide and its formulations. Pharmacol Res 2014; 85: 1–3.
46. Aulton ME. Aulton's Pharmaceutics. The Design and Manufacture of Medicines, 32nd edn. London: Churchill Livingstone, 2006.
47. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 2014; 11: 136.
48. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9–19.
49. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med 2012; 9: 1121–30.
50. Dominguez CM, Martin AD, Ferrer FG, Puertas MI, Muro AL, Gonzalez JM, et al. N-Palmitoylethanolamide in the treatment of neuropathic pain associated with lumbosciatica. Pain Manag 2012; 2: 119–24.
51. Del Giorno R, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther 2015; 4: 169–78.
52. Giugliano E, Cagnazzo E, Soave I, Lo Monte G, Wenger JM, Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur J Obstet Gynecol Reprod Biol 2013; 168: 209–13.
53. Crestani F, Burato A, Michielan F. La palmitoilethanolamide micronizzata aumenta l'analgesia da agopuntura nel dolore da radicolopatia: studio pilota. G Ital Med Riabil MR 2013; 1: 49–54.
54. Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014; 2014: 854560.
55. Desio P. Associazione tra pregabalin e palmitoiletanolamide per il trattamento del dolore neuropatico. Pathos 2010; 4: 9–14.
56. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014; 2014: 849623.
57. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med 2011; 102: 141–7.
58. Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets 2011; 10: 916–20.
59. Indraccolo U, Barbieri F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. Eur J Obstet Gynecol Reprod Biol 2010; 1: 76–9.
60. Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. Int Med Case Rep J 2013; 6: 49–53.
61. Keppel Hesselink JM, Kopsky DJ. Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells. J Pain Res 2013; 6: 239–45.
62. Kopsky DJ, Keppel Hesselink JM. Multimodal stepped care approach with acupuncture and PPAR-alpha agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct Med 2012; 1: 53–5.
63. Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. Pain Med 2010; 11: 781–4.
64. Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions. Translating clinical research to dental practice. J Am Dent Assoc 2013; 144: 898–908.
65. Ramagopalan S, Skingsley AP, Handunnetthi L, Klingel M, Magnus D, Pakpoor J, et al. Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study. F1000Res 2014; 3: 77.
66. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005; 365: 176–86.
67. Andresen SR, Bing J, Hansen RM, Biering-Sørensen F, Johannesen IL, Hagen EM, et al. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: A randomized, double-blind, placebo-controlled trial. Pain 2016; doi: 10.1097/j.pain.0000000000000623